Arterial stiffness in patients with acute coronary syndrome without persistent ST segment elevation combined with chronic kidney disease and arterial hypertension and its correction with antihypertensive therapy

Pribylov Sergey A., Yakovleva Margarita V., Pribylov Vladislav S., Barbashina Tatiana A., Leonidova Kristina O., Pribylova Nadezda N.
{"title":"Arterial stiffness in patients with acute coronary syndrome without persistent ST segment elevation combined with chronic kidney disease and arterial hypertension and its correction with antihypertensive therapy","authors":"Pribylov Sergey A., Yakovleva Margarita V., Pribylov Vladislav S., Barbashina Tatiana A., Leonidova Kristina O., Pribylova Nadezda N.","doi":"10.21626/vestnik/2022-1/03","DOIUrl":null,"url":null,"abstract":"Objective: to study arterial stiffness in patients with acute coronary syndrome without ST elevation, who have hypertension (AH) and stage 2-3A chronic kidney disease (CKD) and to assess the ability of angiotensin-converting enzyme inhibitor perindopril and angiotensin receptor antagonist losartan to reduce arterial stiffness in these patients. Materials and Methods. We studied 44 patients with ACS without ST elevation combined with CKD stage 2-3A, AH (the 1st group). The comparison groups were the ACS without ST segment elevation, AH patients with normal renal function (the 2nd group, n=27) and the 3rd group (n=44) of patients with chronic CHD, AH and CKD. Group 1 patients were divided into 2 subgroups taking perindopril or losartan. The parameters of vascular wall stiffness (pulse wave velocity (PWV), cardio-ankle vascular index (CAVI), ankle brachial index (ABI), aortic augmentation index (AI), central systolic and pulse aortic pressure, peripheral blood pressure (BP), estimated glomerular filtration rate (GFR) were assessed.) Results. The patients with ACS without ST elevation combined with 2-3A stages of CKD and AH had a significantly higher cPAP, AI, PWV, and CAVI than the patients of the 2nd group. During 3 months of complex therapy with perindopril, a decrease in PWV, cSAP, cPAP, AI was observed. There were no significant differences in the effects of perindopril and losartan on peripheral and central blood pressure, on renal function, on arterial stiffness parameters. Conclusion. Patients with AH and CKD stage 2-3A have more pronounced arterial stiffness compared to similar patients with normal GFR. Antihypertensive therapy with perindopril and losartan allows to reach target levels of peripheral BP, significantly reduce central aortic pressure and improve elastic properties of the arterial vascular wall.","PeriodicalId":24060,"journal":{"name":"Курский научно-практический вестник «Человек и его здоровье»","volume":"136 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Курский научно-практический вестник «Человек и его здоровье»","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21626/vestnik/2022-1/03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: to study arterial stiffness in patients with acute coronary syndrome without ST elevation, who have hypertension (AH) and stage 2-3A chronic kidney disease (CKD) and to assess the ability of angiotensin-converting enzyme inhibitor perindopril and angiotensin receptor antagonist losartan to reduce arterial stiffness in these patients. Materials and Methods. We studied 44 patients with ACS without ST elevation combined with CKD stage 2-3A, AH (the 1st group). The comparison groups were the ACS without ST segment elevation, AH patients with normal renal function (the 2nd group, n=27) and the 3rd group (n=44) of patients with chronic CHD, AH and CKD. Group 1 patients were divided into 2 subgroups taking perindopril or losartan. The parameters of vascular wall stiffness (pulse wave velocity (PWV), cardio-ankle vascular index (CAVI), ankle brachial index (ABI), aortic augmentation index (AI), central systolic and pulse aortic pressure, peripheral blood pressure (BP), estimated glomerular filtration rate (GFR) were assessed.) Results. The patients with ACS without ST elevation combined with 2-3A stages of CKD and AH had a significantly higher cPAP, AI, PWV, and CAVI than the patients of the 2nd group. During 3 months of complex therapy with perindopril, a decrease in PWV, cSAP, cPAP, AI was observed. There were no significant differences in the effects of perindopril and losartan on peripheral and central blood pressure, on renal function, on arterial stiffness parameters. Conclusion. Patients with AH and CKD stage 2-3A have more pronounced arterial stiffness compared to similar patients with normal GFR. Antihypertensive therapy with perindopril and losartan allows to reach target levels of peripheral BP, significantly reduce central aortic pressure and improve elastic properties of the arterial vascular wall.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
急性冠状动脉综合征合并慢性肾病合并高血压患者动脉僵硬及降压治疗
目的:研究合并高血压(AH)和2-3A期慢性肾脏疾病(CKD)的急性冠状动脉综合征无ST段抬高患者的动脉僵硬度,并评估血管紧张素转换酶抑制剂perindopril和血管紧张素受体拮抗剂氯沙坦降低这些患者动脉僵硬度的能力。材料与方法。我们研究了44例ACS无ST段抬高合并CKD期2-3A, AH的患者(第一组)。对照组为无ST段抬高的ACS患者、肾功能正常的AH患者(第二组,n=27)和合并慢性冠心病、AH和CKD患者的第三组(n=44)。组1患者分为2个亚组,分别使用培哚普利或氯沙坦。评估血管壁刚度(脉搏波速度(PWV)、心踝血管指数(CAVI)、踝肱指数(ABI)、主动脉增强指数(AI)、中央收缩压和脉主动脉压、外周血压(BP)、肾小球滤过率(GFR)等参数。)结果。ACS无ST段抬高合并CKD、AH 2-3A期患者cPAP、AI、PWV、CAVI明显高于第二组患者。在培哚普利联合治疗3个月期间,观察到PWV、cSAP、cPAP、AI下降。培哚普利和氯沙坦对外周血和中枢血压、肾功能、动脉硬度参数的影响无显著差异。结论。与GFR正常的类似患者相比,AH和CKD 2-3A期患者有更明显的动脉僵硬。使用培哚普利和氯沙坦进行降压治疗可以使外周血压达到目标水平,显著降低中央主动脉压,改善动脉血管壁的弹性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Determination of Mexidol in tablets by the method of derivative spectrophotometry Зонирование территорий исторических центров Уральских городов Phenotypic approach to personalization of pharmacotherapy in patients with congenetive heart failure with low left ventricular ejection fraction Development of a method for determining related impurities in a new biologically active compound of cardioprotective action by capillary electrophoresis Alliance of two pandemics: COVID-19 and diabetes mellitus
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1